Arovella Therapeutics Ltd has released a press release.
SUDA Submits Application For ArTiMist
Filed with ASX ·
6ix hasn’t read this filing yet.
Arovella Therapeutics Limited on 6ix
Story so far
Earlier from Arovella Therapeutics
- SUDA Extends Maturity of Convertible Notes
- SUDA Enters Feasibility Agreement With Pfizer
- SUDA expands patent coverage for SUD-003 and SUD-004
- SUDA Announces Strong Revenue For Westcoast
- SUDA Update On Discussions with Berlin Pharma
Later from Arovella Therapeutics
- SUDA Completes $1.5m Capital Raising
- Placement, Interest Shares and Convertible Note Prospectus
- SUDA Meeting For Zolpimist Into Europe
- SUDA Signs Term Sheet To Acquire Anti-Cancer Agent
- SUDA Enters Licence Agreement With Teva
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics